Citi keeps 'buy' rating on Oxford Nanopore as profitability target holds despite revenue miss

Oxford Nanopore reported H2 2025 adjusted EBITDA of -£38m, beating consensus (-£42m) and Citi's -£45m, but issued lower-than-expected revenue guidance for 2026 and 2027 citing US NIH funding cuts and a difficult trading environment in China. The company reaffirmed targets of adjusted EBITDA breakeven in 2027 and positive cash flow in 2028, and Citi retained its 'buy' rating while noting the abandonment of a prior >30% pa revenue growth target. Shares were down 1.6% at 112.9p mid-afternoon.

Analysis

Market structure: Oxford Nanopore’s weaker 2026–27 revenue guidance signals demand softness in academic and China markets, benefiting competitors with stronger clinical/reagent recurring revenue (e.g., Illumina ILMN, Thermo Fisher TMO) while hurting vendors concentrated in grant-funded research. Pricing power for sequencing kit/reagent makers will face pressure as buyers delay upgrades; ONT’s reaffirmed EBITDA breakeven (2027) suggests it is prioritising margin restoration over share capture, which can stabilize margins industry‑wide. Cross-asset: expect modest widening in small-cap biotech credit spreads, a 10–30% lift in ONT implied volatility near updates, and minor sterling downside if UK biotech disappointments persist.

Risk assessment: Tail risks include an additional 10–20% cut in NIH grants, China market exclusion, or a failure to hit the 2027 breakeven that forces dilutive capital raises; each would drive >30% downside in ONT equity. In the immediate term (days) trade flows and options vol will dominate; short-term (weeks–months) execution of cost saves and product launch timing matters; long-term (2027–28) cash flow conversion is the key binary. Hidden dependencies: recurring consumables attach rates, China distribution/licensing, and timing of new reagent launches are leverage points. Catalysts: UK/US fiscal appropriations (next 60 days), ONT H1 2026 trading update, and China regulatory clarity.

Trade implications: Tactical long-small, hedge-heavy positions in ONT make sense: exposure should be sized for binary breakeven (2–4% notional), with a protective put or call spread to cap downside. Relative-value: long ONT vs short PACB (PacBio) captures ONT’s clearer margin path vs PacBio’s history of dilution; unwind on either material product outperformance or missed 2026 guide. Options: use long-dated (12–18 month) call spreads to play recovery and buy 6–12 month puts to hedge near-term execution risk. Sector rotation: reduce pure academic/reagent cyclicals and raise weightings to diagnostics/recurring-revenue names (ILMN, TMO) over 3–12 months.

Contrarian angles: Consensus focuses on headline revenue trimming but underestimates value of achieving EBITDA breakeven—if ONT hits 2027 breakeven, re-rating could be >50% as multiple compressions reverse. The market may be underpricing the durability of reagent attach-rates and recurring service revenue; conversely, management’s pivot to profits risks under-investing in R&D and ceding long-term share to rivals. Historical parallels: past sequencing cycles show companies can re-rate sharply once cash-flow visibility improves (example: Illumina’s post‑integration re-ratings), but failures to reinvest have led to longer-term share erosion. Unintended consequence: achieving breakeven via aggressive cost cuts could lower future TAM expansion and reduce long-term upside.

Key Decisions for Investors

• Establish a 2–3% long position in Oxford Nanopore (LSE:ONT) at current levels (~113p); scale to 4% only if price falls to ≤100p. Set a hard stop: cut to 0% if H1 2026 revenue misses guidance by >10% or management delays 2027 adjusted EBITDA breakeven beyond 6 months.
• Implement a pair trade: long ONT 2% vs short PACB (PacBio) 2% notional for 12 months, betting ONT’s path to EBITDA breakeven and lower dilution risk outperforms PacBio; close the pair if PACB announces superior product adoption or ONT confirms >5% QoQ revenue deterioration.
• Use options to express asymmetric risk: buy a Jan‑2027 ONT call spread (buy 120p / sell 180p) sized to 0.5% portfolio risk and simultaneously buy a 6–12 month 85–100p protective put for positions >1% to cap near-term downside.
• Monitor NIH appropriations and China sales signals over the next 30–60 days: if NIH grant allocation affecting genomics declines >5% YoY or ONT issues another >15% China guidance cut in H1 2026, reduce research-exposed sequencing/reagent positions by an incremental 5–10% and rotate into ILMN or TMO (increase weight by 2–4%).